10X Genomics, Inc. SEC Filings

10x Genomics, Inc. reported an insider stock transaction by a senior executive. On 11/24/2025, a reporting person who serves as both a director and as President and Chief Scientific Officer sold 8,283 shares of Class A common stock of 10x Genomics, Inc. (TXG) at a price of $18.9983 per share. According to the explanation provided, the shares were sold to cover tax withholding obligations that arose when restricted stock units vested, meaning the transaction was tied to equity compensation rather than a discretionary open-market sale.

After this transaction, the reporting person beneficially owned 432,605 shares of Class A common stock in direct form. The Form 4 was filed for a single reporting person and does not report any derivative securities activity.

10x Genomics, Inc. (TXG) Chief Executive Officer and Director Serge Saxonov reported a sale of Class A common stock in a Form 4 filing. On 11/24/2025, he sold 13,261 shares at an average price of $18.9983 per share in a transaction coded "S," which the notes explain was to cover tax withholding obligations from vesting restricted stock units.

After this transaction, Saxonov beneficially owns 1,021,556 Class A shares directly. He also reports indirect ownership of 27 shares through the Andromeda Trust, 213,250 shares through the Y/S Descendants' Trust, and 58,000 shares through the Y/S Pot Trust, where he serves as trustee.

10x Genomics (TXG) announced a planned legal leadership transition. Eric S. Whitaker will retire as Chief Legal Officer effective January 1, 2026, after more than eight years with the company. He will remain an employee with reduced compensation and serve as Strategic Counsel, continuing to advise on ongoing legal matters.

Dr. Randy Wu, currently Vice President of Intellectual Property and Litigation, has been appointed General Counsel and Secretary effective January 1, 2026. Wu joined the company in August 2016 following his tenure at Orrick, Herrington & Sutcliffe LLP, and holds a Ph.D. in Biophysics (UCSF) and a J.D. (Stanford). CEO Serge Saxonov highlighted Whitaker’s leadership through key milestones, and emphasized continuity with Wu’s internal promotion.

10x Genomics (TXG) reported Q3 2025 results with revenue of $149.0 million and a net loss of $27.5 million. Gross margin was 67%. Products and services revenue fell 2% year over year as instruments declined 37% to $12.0 million, while consumables rose 1% to $127.9 million and services grew 29% to $8.1 million.

Year-to-date, revenue reached $476.8 million$45.8 million of license and royalty revenue tied to settlements with Vizgen and Bruker, alongside a $49.9 million gain on settlement. Cash, cash equivalents, and marketable securities totaled $482.1 million as of September 30, 2025.

The company closed the Scale Biosciences asset acquisition with $9.2 million cash and $13.5 million in stock (1,099,992 shares), recorded $22.4 million of contingent consideration at fair value, and expects a $20.0 million payment in Q1 2026. A May 2025 restructuring recorded $6.0 million in charges. Management noted revenues are expected to moderately increase sequentially in Q4 2025 and gross margin may fluctuate with mix and non-recurring items.

10x Genomics (TXG) furnished an 8-K announcing quarterly results. The company reported that it issued a press release with financial results for the quarter ended September 30, 2025, and attached it as Exhibit 99.1. The disclosure under Item 2.02 is furnished and not deemed filed under Section 18 of the Exchange Act.

10x Genomics’ Class A common stock trades on Nasdaq under the symbol TXG. The exhibit list includes the press release dated November 6, 2025 and the Inline XBRL cover page file.

Serge Saxonov, Chief Executive Officer and Director of 10x Genomics (TXG), filed a Form 4 reporting a transaction dated 09/12/2025 in which 900 shares of Class A common stock were disposed (code G). After the reported transaction, Mr. Saxonov directly beneficially owns 1,034,817 shares of Class A common stock. The filing also discloses substantial indirect and convertible holdings held in multiple trusts for which he serves as trustee, including convertible Class B shares that can convert into Class A shares and derivative holdings underlying 1,192,040 and 1,750,000 Class A shares as reported. Footnotes identify transfers on July 18, 2025 and several irrevocable trusts (each holding 250,000 shares) for which he is sole trustee, indicating estate or trust structuring of substantial ownership.

Serge Saxonov, who serves as Chief Executive Officer and a director of 10x Genomics, Inc. (TXG), reported a transaction on 08/22/2025 in which 9,348 shares of Class A common stock were sold at a price of $13.787 per share. The filing indicates the sale was made to cover tax withholding obligations related to the vesting of restricted stock units. After the reported transaction, the filing shows 945,892 shares held directly and additional indirect holdings reported as: 27, 89,825, 213,250, and 58,000 shares, each held via trusts for which the reporting person serves as trustee. The Form 4 was signed by an attorney-in-fact on 08/26/2025.

10x Genomics insider sale by CFO Adam Taich, the company's Chief Financial Officer and reporting person, reported a sale of 22,315 shares of Class A Common Stock on 08/22/2025 at a price of $13.787 per share. Following the sale, Mr. Taich beneficially owned 309,273 shares, reported as direct ownership. The filing explains the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Taich on 08/26/2025.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (Ticker: TXG), reported a sale of 7,486 shares of Class A common stock on 08/22/2025 at a price of $13.787 per share. The filing states the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. After the transaction, Mr. Hindson beneficially owned 440,888 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Hindson on 08/26/2025. The filing lists Mr. Hindson as both a director and an officer of the issuer.